- Conditions
- Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain
- Interventions
- NT-II™ (240 mg), NT-II™ 480 mg, Glucosamine/Chondroitin
- Dietary Supplement
- Lead sponsor
- Hofseth Biocare ASA
- Industry
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 3:46 AM EDT